Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00100256
Status:
RECRUITING
Last Update Posted:
2022-11-07
First Post:
2004-12-27
Brief Title:
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Sponsor:
Andarix Pharmaceuticals
Organization:
Andarix Pharmaceuticals
Study Overview
Official Title:
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Status:
RECRUITING
Status Verified Date:
2022-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the maximum dose that is safely tolerated of the experimental drug Rhenium Re 188 P2045 This will be done by first treating patients at relatively low doses of Rhenium Re 188 P2045 observing them closely to assure that there are no bad side effects then increasing the dose when we are confident that it is safe to do so
Detailed Description:
We want to learn more about the side effect profile of both Technetium Tc 99m P2045 and Rhenium Re 188 P2045 and will do that by observing you closely after you receive the drug and by conducting multiple tests as well as by asking you how you feel We want to also learn if there is any benefit in terms of lung cancer tumor reduction as a result of treatment with Rhenium Re 188 P2045 This study has previously been posted by Berlex Inc Andarix Pharmaceuticals is the sponsor of the trial
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 306509 | None | None | None |